Steel City,
I want you to know that I respect you because I have noted that you are always quick to apologize to others. You mentioned that the intensity has picked up on this board and you wonder about that. I want to assure you that my posting on this board has no hidden agenda. I don't want to mislead anyone. I continue to do lots of research on BioCurex, and I have not found anything that would warrant selling at this time. Quite the contrary. This stock could make the current investors a lot of money.
For the benefit of all those who read this board, all of the things that are discussed here do not always have to be of a positive nature. It is unrealistic to believe there are not any negative aspects concerning BioCurex. One specific negative has to do with the "home brew" assay that BioCurex currently uses to test blood samples. Here is what BioCurex management said on March 31, 2005:
"First; There are several types of blood tests that can be used to detect and diagnosis cancer. For example, BioCurex retains all rights for the radio-immunoassay (RIA) test which was used for many of its excellent cancer detection reports in scientific presentations and the subject of previous press releases. This product is not the primary type of test used in high throughput automatic lab systems, but a market exists for this test in North America and other countries. Rapid-type tests are another interest area."
What wasn't said in the quote above is that BioCurex's radio-immunoassay (RIA) test involves the use of radioactive material, and without much doubt, produces radioactive waste. Therefore, don't hold your breath waiting for such a test to bring in much revenue.
Fortunately Abbott, for more than a year, has been working to design a completely new RECAF assay that will run on their Architect analyzers. The new test must fit within the constraints of their Architect analyzers and therefore the first milestone of the BioCurex/Abbott deal is a feasibility review to determine if that is possible. It appears that Abbott thought a new test had a good chance of being possible or they would have not taken on the project which consumes the time of Abbott's scientists. There is also the matter of the 200K up front money that Abbott paid. The risk that Abbott is taking with the RECAF technology is a calculated risk. All things considered, Abbott had to believe they would succeed. And the belief that Abbott will succeed, and the fact that Abbott has been working on this for more than a year without returning the technology, is exactly what each of us should be focusing on with this investment. Hang in there. kag
AI
